Voting Results of the Annual General Meeting held on 30th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem Limited (BSE: 543594) held its AGM on August 30, 2025, via video conferencing, with all 7 resolutions passed unanimously. Shareholders approved the audited financial statements for FY ending March 31, 2025, the re-appointment of Mr. Nirav Soni as a director, and the appointment of Mr. Parin Bhavsar as a Non-Executive Independent Director. Three related party transactions were approved, covering dealings with Dhara Pharmachem Private Limited, Dipan Pharmachem Private Limited, and Cedac Medicorp, with promoter group votes excluded from these resolutions due to their interest. The final resolution approved an increase in the company's Authorised Share Capital and a corresponding alteration to the Capital clause of the Memorandum of Association. Out of 1,789 shareholders on record date, 20 attended via VC and 25.47% of outstanding shares were polled, with 100% voting in favour on every resolution.
The unanimous approval of all resolutions signals strong shareholder alignment and removes governance overhang. The approved authorised capital increase provides room for potential fundraising or stock splits, while the related party clearances allow the company to continue normal business operations with associated entities. No material negative signals for shareholders.